リコンビナントタンパク質＿精製したリコンビナントタンパク質 » リコンビナントサイトカイン-免疫活性タンパク質 » LR3-IGF-I, Human (Receptor Grade)
LR<sup>3</sup>-IGF-I (Receptor Grade), Human

ED50 < 10.0 ng/ml, measured by the dose dependent proliferation of CHO cells, corresponding to a specific activity of > 1.0 × 105 units/mg.

LR<sup>3</sup>-IGF-I (Receptor Grade), Human

Lane 1: 2 μg of LR3-IGF-I (Receptor Grade), Human, non-reducing (NR)
Lane 2: 2 μg of LR3-IGF-I (Receptor Grade), Human, reducing (R)
> 95% as analyzed by SDS-PAGE

LR3-IGF-I (Receptor Grade), Human

IGF-1 is a well-characterized basic peptide secreted by the liver that circulates in the blood. It has growth-regulating, insulin-like, mitogenic activities. IGF-1 is a growth factor that has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to IGF-2, which is also a major fetal growth factor. Human Long R3 Insulin-like Growth Factor-1 (rhLR3IGF-1) contains an 83 amino acid analog of human IGF-I. Compared to the complete human IGF-I sequence, an addition of the rhLR3IGF-1 includes the substitution of an Arg for the Glu at position 3 (hence R3)and a13 amino acid extension peptide at the N-terminus. An enhanced potency is due to the markedly decreased binding of human Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs.
Z03177
¥9,606.00

Ask us a question
Product Introduction
Species Human
Protein Construction

Expressed with additional N-terminal sequence (MFPAMPLSSLFVNGPRT).

LR3-IGF-I (Leu53-Ala118)
Accession # P05019
Purity > 95% as analyzed by SDS-PAGE
Endotoxin Level < 1 EU/μg of protein by gel clotting method
Biological Activity ED50 < 10.0 ng/ml, measured by the dose-dependantproliferation of CHO cells, corresponding to a specific activity of > 1.0 × 105 units/mg.
Expression System E. coli
Apparent Molecular Weight ~9.1 KDa, on SDS-PAGE under reducing conditions.
Formulation Lyophilized after extensive dialysis against 50 mM acetic acid.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in 10 mM HCl up to 1mg/ml.
Storage & Stability Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

Examples
  • LR<sup>3</sup>-IGF-I (Receptor Grade), Human
    • LR<sup>3</sup>-IGF-I (Receptor Grade), Human

    ED50 < 10.0 ng/ml, measured by the dose dependent proliferation of CHO cells, corresponding to a specific activity of > 1.0 × 105 units/mg.

  • LR<sup>3</sup>-IGF-I (Receptor Grade), Human
    • LR<sup>3</sup>-IGF-I (Receptor Grade), Human

    Lane 1: 2 μg of LR3-IGF-I (Receptor Grade), Human, non-reducing (NR)
    Lane 2: 2 μg of LR3-IGF-I (Receptor Grade), Human, reducing (R)
    > 95% as analyzed by SDS-PAGE


Background
Target Background IGF-1 is a well-characterized basic peptide secreted by the liver that circulates in the blood. It has growth-regulating, insulin-like, mitogenic activities. IGF-1 is a growth factor that has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to IGF-2, which is also a major fetal growth factor. Human Long R3 Insulin-like Growth Factor-1 (rhLR3IGF-1) contains an 83 amino acid analog of human IGF-I. Compared to the complete human IGF-I sequence, an addition of the rhLR3IGF-1 includes the substitution of an Arg for the Glu at position 3 (hence R3)and a13 amino acid extension peptide at the N-terminus. An enhanced potency is due to the markedly decreased binding of human Long-R3-IGF-I to IGF binding proteins which normally inhibit the biological actions of IGFs.
Synonyms LR3 Insulin-like Growth Factor-I; LR3-IGF-I

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.